Transaction DateRecipientSharesTypePriceValue
21st September 2020Sean A. Mc Carthy20,500Exercise of derivative$6.61$135,601.35
29th May 2020Sean A. Mc Carthy1,158Grant/award etc.$5.11$5,915.64
12th May 2020Sean A. Mc Carthy36,000Exercise of derivative$1.13$40,820.40
12th May 2020Sean A. Mc Carthy36,000Open or private sale$15.00$540,000.00
30th November 2019Sean A. Mc Carthy1,080Grant/award etc.$5.32$5,746.68
31st May 2019Robin Knifsend1,812Grant/award etc.$8.21$14,878.33
31st May 2019Sean A. Mc Carthy695Grant/award etc.$8.21$5,706.65
31st May 2019Lloyd A Rowland1,812Grant/award etc.$8.21$14,878.33
8th April 2019Frederick W Gluck3,900Bona fide gift$0.00
8th April 2019Frederick W Gluck3,900Bona fide gift$0.00
Cytom X Therapeutics
Cytom X Therapeutics logo

Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 9/10.


CytomX Therapeutics, Inc. engages in the development of antibody therapeutics for the treatment of cancer based on its Probody therapeutic technology platform. Its pipeline includes immunotherapies, probody drug conjugates, T cell engaging bispecifics, and other multiple programs.


Ticker: CTMX
Sector: Health Technology
Industry: Biotechnology
SEC Central Index Key (CIK): 1501989
Employees: 158
Exchange: NASDAQ
Auditor Opinion:

Disclosure Language changes
Red Flags
Fundamentals